Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress ...Middle East

Highlights from the Data Presentation Initial immunogenicity (n=9) and ongoing safety data (n=13) presented in chronically HBV-infected patients following a single, low dose, prime-only intramuscular injection of VRON-0200 VRON-0200 was well tolerated, with no serious adverse events...

Hence then, the article about virion therapeutics reports positive first in human first in class phase 1b immunogenicity data of vron 0200 a novel checkpoint modifier for hbv functional cure at easl congress was published today ( Wednesday 05/06/2024 - 09:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress )

Also on site :

• ABC Explains 'General 'Hospital' Preemption, Sets New Airdate
• Will Trent's Erika Christensen On The Significance Of Angie Having A Girl, Her Engagement To Seth, And What Changes (And Doesn't) With Will
• US trade with Southeast Asia and Taiwan surging despite Trump tariffs